Project 1 of the CREATE Pharmacogenetic Research Network is focused on the identification of polymorphism in members of the pathways regulating drug activity. In this project, we propose to survey the 43 candidate genes fully, identifying DNA sequence variations from the promoters to the 3'-untranslated regions, encompassing all the exons plus the exon/intron boundaries. We will do so by the most cost effective and efficient approach developed by our group; namely, comparative pooled DNA sequencing of a moderate number of individuals (n=100). In addition, we will use a computational biology approach to evaluate the variants identified and predict which variants are most likely to be of functional importance. Specifically, we propose the following aims: 1: Design and validate PCR assays for the 5' regulatory region, exons, and 3' untranslated regions for 43 candidate genes. 2: Sequence and analyze all PCR fragment from pooled DNA samples 3: Deposit all variant to dbSNP. : Provide computational prediction of functional significance of variants found. 5: Develop an iterative algorithm for incorporation of biological data into prediction ov variant function. With these approaches, we will not only identify a comprehensive panel of gene-associated variants for the pharmacogenetic community, but also provide a framework to select the most promising variants (as predicted by computational approach) for analysis in the other project of this network.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01GM063340-01
Application #
6495863
Study Section
Special Emphasis Panel (ZRG1)
Project Start
2001-08-01
Project End
2005-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Patel, Jai N; Jiang, Chen; Hertz, Daniel L et al. (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121:1025-31
Marsh, Sharon; King, Cristi R; Van Booven, Derek J et al. (2015) Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics 16:441-8
Hariani, Gunjan D; Lam, Ernest T; Lam, Ernest J et al. (2014) Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Res Notes 7:360
McWhinney-Glass, Sarah; Winham, Stacey J; Hertz, Daniel L et al. (2013) Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 19:5769-76
Trammel, Morgan; Roederer, Mary; Patel, Jai et al. (2013) Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep 15:276-85
Motsinger-Reif, Alison A; Jorgenson, Eric; Relling, Mary V et al. (2013) Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 23:383-94
Crowley, James J; Kim, Yunjung; Szatkiewicz, Jin Peng et al. (2012) Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 23:322-35
He, Y J; McLeod, H L (2012) Ready when you are: easing into preemptive pharmacogenetics. Clin Pharmacol Ther 92:412-4
Hoskins, Janelle M; Ong, Pei-Shi; Keku, Temitope O et al. (2012) Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. PLoS One 7:e41954
Crowley, J J; Adkins, D E; Pratt, A L et al. (2012) Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics J 12:147-55

Showing the most recent 10 out of 181 publications